These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9845953)

  • 1. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives.
    Takeuchi M; Sakamoto S; Kawamuki K; Kurihara H; Nakahara H; Isomura Y
    Chem Pharm Bull (Tokyo); 1998 Nov; 46(11):1703-9. PubMed ID: 9845953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives.
    Takeuchi M; Sakamoto S; Yoshida M; Abe T; Isomura Y
    Chem Pharm Bull (Tokyo); 1993 Apr; 41(4):688-93. PubMed ID: 8508470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
    Cohen H; Solomon V; Alferiev IS; Breuer E; Ornoy A; Patlas N; Eidelman N; Hägele G; Golomb G
    Pharm Res; 1998 Apr; 15(4):606-13. PubMed ID: 9587958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive dose-response relationships across three generations of bisphosphonates.
    Sietsema WK; Ebetino FH; Salvagno AM; Bevan JA
    Drugs Exp Clin Res; 1989; 15(9):389-96. PubMed ID: 2630251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats.
    Takahashi K; Shirahata A; Fukushima S; Kokubo S; Teramura K; Usuda S
    Jpn J Pharmacol; 1998 Feb; 76(2):155-63. PubMed ID: 9541278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
    Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
    J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
    Green JR; Müller K; Jaeggi KA
    J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
    Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
    Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
    Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
    Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).
    Lawson MA; Ebetino FH; Mazur A; Chantry AD; Paton-Hough J; Evans HR; Lath D; Tsoumpra MK; Lundy MW; Dobson RL; Quijano M; Kwaasi AA; Dunford JE; Duan X; Triffitt JT; Jeans G; Russell RGG
    J Bone Miner Res; 2017 Sep; 32(9):1860-1869. PubMed ID: 28337806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
    Mühlbauer RC; Bauss F; Schenk R; Janner M; Bosies E; Strein K; Fleisch H
    J Bone Miner Res; 1991 Sep; 6(9):1003-11. PubMed ID: 1838661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
    Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
    Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
    Sanders JM; Song Y; Chan JM; Zhang Y; Jennings S; Kosztowski T; Odeh S; Flessner R; Schwerdtfeger C; Kotsikorou E; Meints GA; Gómez AO; González-Pacanowska D; Raker AM; Wang H; van Beek ER; Papapoulos SE; Morita CT; Oldfield E
    J Med Chem; 2005 Apr; 48(8):2957-63. PubMed ID: 15828834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
    Szabo CM; Martin MB; Oldfield E
    J Med Chem; 2002 Jul; 45(14):2894-903. PubMed ID: 12086477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of pamidronate in patients with metastatic bone disease.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
    Kotsikorou E; Oldfield E
    J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel bisphosphonates with dual activities on bone in vitro.
    Xie Y; Ding H; Qian L; Yan X; Yang C; Xie Y
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3267-70. PubMed ID: 15936189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.